Join the Breast Cancer group to help and get support from people like you.
Breast Cancer News (Page 16)
Related terms: Breast Cancer, inflammatory, Cancer, Breast, Carcinoma, Ductal, Carcinoma, Lobular, Ductal Carcinoma in Situ (DCIS), Ductal Carcinoma in Situ, DCIS
FDA Medwatch Alert: Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication - Potential Medication Errors Resulting from Name Confusion
ISSUE: The FDA notified health care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla (ado-trastuzumab emtansine) in some medication-related...
FDA Approves Lymphoseek to Help Locate Lymph Nodes in Patients with Certain Cancers
March 13, 2013 – The U.S. Food and Drug Administration today approved Lymphoseek (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph...
FDA Approves Kadcyla for Late-Stage Breast Cancer
February 22, 2013 – The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. ...
FDA Approves Afinitor for Advanced Breast Cancer
July 20, 2012 – The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced...
FDA Approves Perjeta (pertuzumab) for People With HER2-Positive Metastatic Breast Cancer
South San Francisco, Calif. – June 8, 2012 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Perjeta (pertuzumab). Perjeta is...
FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
THOUSAND OAKS, Calif., September 19, 2011, 2011 /PRNewswire/ – Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia (denosumab) as a...
FDA Approves Halaven for Late-Stage Breast Cancer
SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have...
FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 20, 2010 - Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab)...
FDA Approves New Dosing for Faslodex (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ – AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of Faslodex (fulvestrant) Injection,...
GSK's Tykerb Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
PHILADELPHIA, Jan. 29 /PRNewswire/ – GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using Tykerb...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Cancer
Related drug support groups
methotrexate, fluorouracil, anastrozole, letrozole, Arimidex, Herceptin, Keytruda, Femara, trastuzumab, tamoxifen, Ibrance